Monthly Archives December 2019

Cured Of Crohn’s? That’s what Joshua states

Joshua is CURED of Crohn’s!?!? Interview with Joshua Nachman, MS, CNS, LDN, CPT Brought To You By The One Great Gut Foundation One Great Gut Foundation Purpose: We teach our community how to Thrive with IBD Crohn’s Colitis by working together to accelerate healing, reverse dis-ease, and bring on the super poops that everyone deserves. Fun fact: A super poop is an ideal donor for a Fecal Transplant, arguably the world’s best probiotic. In other words – it’s good shit. Literally! Joshua is the owner of Balanced Bodies Balanced Minds and holds a Master of Science in Nutrition and Integrative
Read More

Categories: Case Study, Crohn's Disease, DIAGNOSTIC TESTING, MOVE, Relationships, RESEARCH, Stories, and STORIES-OF-HOPE.

US FDA approves Stelara for ulcerative colitis

Do you find these articles helpful? Please donate today so we may continue this service so humanity may prosper in a peaceful world with a peaceful microbiome This past October, the U.S. Food and Drug Administration approved ustekinumab (Stelara by Janssen), a human IL-12 and IL-23 antagonist. This is based on data from a phase 3 UNIFI trial, which demonstrated that ustekinumab induced and maintained clinical remission in a significantly greater proportion of adults with moderately to severely active UC compared with placebo. Trial And Study Results Janssen said at the time the UNIFI data was released that at Week
Read More

Categories: Biologics, C-reactive protein (CRP), CalProctetin, Colonoscopy, Crohn's Disease, Nutrition, One Great Gut Collection, Pharmaceuticals, RESEARCH, Resources, STORIES-OF-HOPE, The Crohn's And Colitis Summit, TREATMENT, and Ulcerative Colitis.

Researchers discover critical link to controlling inflammation in Crohn’s disease

To aggregate the most appropriate IBD news we are republishing this article. This was first reported by Case Western Reserve University in MedicalXpress. We updated the article for further accuracy. (Thank You Dr. Peter Spiegel for bringing this breakthrough to our attention) Investigators at the Case Western Reserve University School of Medicine discovered that blocking interleukin-1α (IL1α), a protein that controls inflammation in the gut, markedly decreases the severity of intestinal inflammation in a mouse model of Crohn’s disease (CD). The anti-inflammatory effects of the biological therapies used to neutralize IL1α were similar to those of steroids, which represent what
Read More

Categories: Biologics, Crohn's Disease, DIAGNOSTIC TESTING, Pharmaceuticals, RESEARCH, and TREATMENT.